Eisai Co., Ltd. ESALF
31.50 USD +1.53 (+5.11%)
At closeOct 30, 2026, 4:00 PM EDT
31.50 Day range 31.50
23.88 52-week range 35.00
- YTD
- +5.95%
- 1 year
- +6.17%
- Market cap
- 8.89B
- EPS (ttm)
- 0.91
- P/E ratio
- 34.62
- YTD return
- +5.95%
- 1-year return
- +6.17%
- Volume
- 150
- Avg volume
- 298
- Open
- 31.50
- Previous close
- 29.97
- Day's range
- 31.50 – 31.50
- 52-week range
- 23.88 – 35.00
- Earnings date
- Nov 10, 2026
1M -0.53 (-1.74%)
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate 0.3677.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | 0.3677 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 0.3408 | 0.3979 | +0.06 | +16.75% |
| May 15, 2026 | Mar 31, 2026 | 0.07825 | -0.07262 | -0.15 | -192.81% |
| Feb 9, 2026 | Dec 31, 2025 | 0.4691 | 0.3889 | -0.08 | -17.10% |
| Nov 4, 2025 | Sep 30, 2025 | 0.33 | 0.2435 | -0.09 | -26.21% |
| Aug 4, 2025 | Jun 30, 2025 | 0.2689 | 0.3563 | +0.09 | +32.50% |
News
Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript 
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug 
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript 
BioArctic Interim Report for the period January - March 2026 
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript 
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study 
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated. 
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency 
BioArctic Interim Report for the period October - December 2025
Your note
Sign in to keep a note on ESALF — it syncs with the Stock Master app.